Axsome Therapeutics Inc

Key Account Manager – Ontario & Western Canada

Canada

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
BiopharmaceuticalsIndustries

Requirements

Candidates should possess a Bachelor’s degree, with life sciences, business, or healthcare degrees preferred, and a minimum of 10 years of pharmaceutical, biotech, or healthcare sales experience, including at least 5 years of experience in rare disease or orphan drug sales, specifically through specialty pharmacies. Proven track record of exceeding sales targets and successfully managing a territory is required, along with excellent communication skills and the ability to analyze complex data and develop business plans.

Responsibilities

The Key Account Manager will be responsible for achieving assigned sales targets in a compliant manner, aligning with marketing strategies, collaborating with internal departments and external resources, developing business partnerships with physicians and healthcare staff, identifying key treatment centers, employing a consultative sales approach, addressing product access issues, cultivating relationships with thought leaders, performing additional tasks as needed, and traveling extensively throughout the assigned territory. They will also support adherence to compliance, regulatory requirements, and company SOPs.

Skills

Pharmaceutical sales
Healthcare relationship management
Product promotion
Regulatory compliance
Cross-functional collaboration
Business development

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Key Metrics

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI